Prevencio and Memorial Sloan Kettering Cancer Center Data Demonstrates Significant Correlation of AI-driven HART CVE Blood Test Scores with Development of Adverse Heart Events Following Cancer Radiation Treatment

Data Highlighted at American Society for Radiation Oncology (ASTRO) Scientific Sessions

KIRKLAND, Wash.--(BUSINESS WIRE)--Prevencio, Inc. today announces the presentation of data demonstrating that its Artificial Intelligence (AI) driven HART CVE blood test scores strongly correlate with subsequent adverse cardiac events in lung cancer patients undergoing radiation treatment. Researchers and clinicians from Memorial Sloan Kettering Cancer Center collaborated to test their lung cancer population.

“With cancer patients living longer, understanding the adverse cardiac effects due to cancer treatments, such as radiation therapy, is of utmost importance,” said Annemarie Shepherd, M.D., Assistant Member in Radiation Oncology Cancer Center. “We analyzed serial patient blood samples before, during and after radiation treatment and interestingly found a significant correlation between an increase in the HART CVE scores during radiation and the development of cardiac events in follow up after radiation.”

Charles B. Simone, M.D., Chief Medical Officer of the New York Proton Center and Member in Radiation Oncology at Memorial Sloan Kettering Cancer Center, added, “It is critical that we identify more sensitive means of predicting which patients will have adverse cardiac events from radiation therapy, and we are pleased to collaborate with Prevencio to use their novel machine learning-based HART CVE test to do so.”

In the general cardiac population, HART CVE had previously been reported to be more accurate (86% AUC accuracy) at predicting risk of heart attack, stroke or cardiac death as compared to single protein blood tests, such as high sensitivity troponin (~65% accuracy), and clinical risk scores (~57% AUC accuracy).

“It is gratifying to work with Dr. Shepherd and Dr. Simone and their team at Memorial Sloan Kettering Cancer Center to demonstrate HART CVE’s usefulness in their lung cancer patients,” said Rhonda Rhyne, President and Chief Executive Officer of Prevencio. “We believe our tests will also prove helpful for breast and esophageal cancer patients undergoing radiation therapy.”

In the U.S., lung cancer is the second most common cancer in both men and women, with approximately 235,760 new cases annually. Currently, there are more than 550,000 lung cancer patients in the U.S.

Prevencio recently launched for patient use its two lead tests, HART CVE (for one-year risk of heart attack, stroke, or cardiac death) and HART CADhs (for obstructive heart disease diagnosis). For additional information, visit Prevencio, Inc.

About Prevencio HART Tests: Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics. Employing this novel approach, the Company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications.

Our three lead tests include:

1. HART CVE™ – 1-year risk of heart attack, stroke, or cardiac death
2. HART CADhs™ – obstructive coronary artery disease diagnosis
3. HART KD™ – Kawasaki disease diagnosis

HART test results have been peer-reviewed published 25 times, including at leading cardiovascular meetings—(European Society of Cardiology Congress – 2016, 2018, 2021; American College of Cardiology Scientific Sessions – 2017, 2018, 2019 (2), 2020, 2021; American Heart Association Scientific Sessions – 2017, 2018, 2019; American Diabetes Association Scientific Sessions – 2018, 2019; Pediatric Academic Societies International Sessions – 2021; International Spinal Cord Society Scientific Sessions –2021; ASTRO Scientific Sessions – 2021) and in top-tier journals—(Journal of American College of Cardiology – Mar 2017; American Journal of Cardiology – July 2017; Clinical Cardiology – June 2018; Open Heart – November 2018, May 2019, Jan 2019; Biomarkers in Medicine – June 2020; Journal of American Heart Association – Aug 2020).

About Prevencio, Inc.:
Prevencio's value proposition is "Preventing the Preventable” — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for Cardiovascular Disease conditions. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests. The Company is headquartered in Kirkland, Washington. For additional information, visit Prevencio, Inc.

Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, and size, the accuracy of which is necessarily subject to various uncertainties of development-stage companies. The Company does not undertake to update disclosures contained in this press release.